The
Intellectual Property Owners Association (IPO) will offer a one-hour webinar
entitled "Myriad: Implications of
the U.S. Supreme Court Opinion" on June 18, 2013 beginning at 2:00
pm (ET). A panel consisting of Gregory Castanias of Jones Day (who argued
for Myriad at the Federal Circuit and before the U.S. Supreme Court); Patent Docs author Dr. Kevin Noonan of
McDonnell Boehnen Hulbert & Berghoff; and Paul Golian, Assistant General
Counsel at Bristol-Myers Squibb Company will consider such questions as:
•
How many and which existing gene patents will be challenged in post-grant
proceedings at the USPTO?
•
Will holders of gene patents seek reissue?
•
What does the decision mean for protein therapeutics, and other products that
are arguably "found in nature"?
•
Are claims to isolated polypeptide sequences covering human proteins that are
in therapeutic use no longer valid?
•
Where do comparative diagnostic claims stand after both Myriad and Prometheus?
The registration fee for the webinar is $120 (government and academic rates are available upon request). Those interested in registering for the webinar can do so here.
We've taken a look at the Myriad decision on IPcopy - see http://ipcopy.wordpress.com/2013/06/14/us-supreme-court-rules-that-human-genes-cannot-be-patented-a-look-at-the-myriad-case/
Posted by: Mark Richardson | June 15, 2013 at 04:04 AM